Sirtex Medical Limited

Results for the half year ended 31st December 2016

Nigel Lange, Interim Group CEO

Darren Smith, CFO

Dr David N. Cade, CMO

Kevin Richardson, CEO Americas

Tony Dixon, CEO EMEA

22 February 2017

1H 2017 overview

- Difficult trading conditions experienced in the 1H
- New drug therapies, increased competitive pressures within the liver-directed Interventional Oncology (IO) market, reimbursement
- Global dose sales growth of 5.6% within revised guidance [4-6%]
- Constant currency EBITDA of $33.6 million, ahead of revised guidance [$30-$32m]
- Launch of new clinical study (SIRCCA) in unresectable, first-line intrahepatic cholangiocarcinoma
- Results of the RESIRT pilot study in kidney cancer presented at ESMO 2016
- Long term growth potential remains; SIR-Spheres ~2% penetrated

Financial results



** The Company has no debt*

Constant currency revenue, EBITDA and NPAT

Summary Sales Revenue

- Reported sales revenue: $112.8 million, up 0.2%
- Currency effect: $5.0 million
- Constant currency sales revenue: $117.8 million, up 4.6%

Summary EBITDA

- Reported EBITDA: $29.2 million, down 17.7%
- Currency effect: $4.4 million
- Constant currency EBITDA: $33.6 million, down 5.2%

Summary NPAT

- Reported NPAT: $20.8 million, down 19.8%
- Currency effect: $3.7 million
- Constant currency NPAT: $24.5 million, down 5.4%

Constant currency (CC) was applied by restating the first half of FY17 with the first half of FY16 average rates: Half year: AUD/USD – 0.723, AUD/EUR – 0.655, AUD/SGD – 1.012. A determination of the constant currency effect for sales revenue, EBITDA and NPAT has not been subject to external review or audit or prepared in accordance with Australian Accounting Standards, IFRS or the Corporations Act 2001. Constant currency provides one measure of comparability between the periods.

1H16 - 1H17 reported NPAT reconciliation

$ thousands



Dose sales and sales revenue

Dose sales

Number of units

5 Year CAGR 17.5%



Sales revenue

$'000

5 Year CAGR 25.1%



Margins

Gross margin

%



EBITDA margin

%



NPAT margin

%



- Gross margin, down 70 bps – impact of higher COGS
- EBITDA margin, down 510 bps – Expenses as a % of sales increased
- NPAT margin, down 450 bps

Earnings per share & operating cash flow

Earnings per share
Cents
5 Year CAGR 27.0%



Operating cash flow
$'000



Investment in sales and marketing

Sales and Marketing

$'000

% sales



Treatment site expansion

Number of sites globally

% seq. growth



Clinical and R&D investment

Total Clinical investment *

$'000

% sales



Total R&D investment *

$'000

% sales



** Includes both capitalised and expensed items; clinical additionally excludes SIRFLOX amortisation*

Americas

Americas

5 year dose sales



- Dose sales of 4,248, up 5.5%
- Revenue of $90.1 million, up 0.7%
  - CC revenue, up 5.5%
- 599 treatment sites, up 12.4% on pcp
- 1H Highlights:
  - NCCN Category 2A designation for mCRC
  - 3% increase in CMS reimbursement for CY17
  - Increase in new referrers
- Outlook:
  - Continued investment into sales & marketing
  - Treatment site expansion
  - Preparations for major clinical studies well advanced

Europe, Middle East & Africa (EMEA)

EMEA

5 year dose sales



- Dose sales of 1,269, up 4.1%
- Revenue of $18.2 million, down 4.3%
  - CC revenue, up 0.5%
- 317 treatment sites, up 5.0% on pcp
- 1H Highlights:
  - Updated ESMO Guidelines in mCRC
  - Steady growth across most EU markets
  - Focus on referrers, users and govt. payers
- Outlook:
  - New CEO appointed (Mr Tony Dixon)
  - Achieved reimbursement in France
  - New market entries planned

Asia Pacific (APAC)

APAC

5 year dose sales



- Dose sales of 530, up 10.2%
- Revenue of $4.4 million, up 8.6%
  - CC revenue, up 10.3%
- 144 treatment sites, up 9.1% on pcp
- 1H Highlights:
  - Continued dose sales growth in APAC
  - Continued increase in AU referrers
  - New regulatory approval in S. Korea
- Outlook:
  - New CEO appointed (Mr Reuben Teo)
  - Leverage opportunity in Asian markets
  - Improve patient access via reimbursement

Major clinical studies set to report

SARAH SIR*ve*NIB

- SARAH* results to be presented at: **EASL/ILC meeting 19-23 April 2017**
  - Awarded oral presentation, abstract release expected 5 April, data presented on 22 April
- SIR*ve*NIB* results expected to be presented at: **ASCO meeting, 2-6 June 2017**
  - Abstract release 17 May, unless withdrawn/embargoed
- SARAH/SIR*ve*NIB prospective meta-analysis (VESPRO)* results **2H CY17**

SIRflox FOXFIRE Global

- SIRFLOX/FOXFIRE/FOXFIRE Global* expected to be presented at: **ASCO meeting in Chicago, 2-6 June 2017**
  - Abstract release 17 May, unless withdrawn/embargoed

** Study investigators may also elect to disclose certain data prior to conference dates, at which time Sirtex will make an ASX announcement*
All dates provided represent local time zones (USA, EU)

SIRTeX

Major clinical studies set to report

soramic

- SORAMIC results expected: **1H of CY18**
- Further details on studies, disclosures and commercial positioning to be provided at Sirtex Clinician 'Lunch & Learn' Investor/Analyst Presentation and Webcast on 2 March 2017

Invitation

SIRTeX | SIR-Spheres microspheres

Sirtex Medical Clinician 'Lunch and Learn' Investor/ Analyst Briefing

Thursday, 2 March 2017
12:30pm to 2:30pm
Sydney

You are invited to join us for lunch to hear expert presentations by two globally renowned clinicians in their respective fields of metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC).

Both presenters have extensive experience in undertaking large-scale, international clinical studies of new cancer medicines. The presentations will highlight current perspectives/thinking around the treatment of these two diseases and the role of SIR-Spheres® Y-90 resin microspheres. The presentations will also provide the information necessary to educate analysts/investors on how to interpret the clinical results of the SIRFLOX/FOXFIRE/FOXFIRE Global studies in mCRC and the SARAH and SIRveNIB clinical studies in HCC. The lunch will also include a presentation by Sirtex management on the overall business strategies following the results of the clinical studies.

Sofitel Wentworth Hotel
Melbourne Room, 61-101 Phillip Street
NSW 2000 Sydney

Via Live Webcast at
http://webcast.openbriefing.com/3300/

RSVP Essential (Limited Places)
Amy Crannage
Phone: +61 2 9964 8408
acrannage@sirtex.com

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

SIRTeX

Other studies & patient registries

- Results of RESIRT pilot kidney cancer study presented at ESMO 2016
  - No Serious Adverse Events (SAE) related to treatment, ~95% disease control rate
- Launch of new clinical study (SIRCCA) in unresectable, first-line intrahepatic cholangiocarcinoma (n=180)[1]
  - SIR-Spheres microspheres + CIS-GEM chemotherapy versus CIS-GEM alone
- US RESiN Registry[2] recruiting very strongly, 286 v 200 planned in CY16
  - >500 patients and 50 sites (23 currently) by end of FY17
  - Many benefits: clinical data, reimbursement, regulatory clearances, awareness
- European registry CIRT
  - Up to 1,200 patients, 30-40 sites, all forms of liver tumours (primary, secondary)
  - Benefits similar to RESiN, >500 patients enrolled since late 2014

[1] https://clinicaltrials.gov/ct2/show/NCT02807181

[2] Banovac F, Brown DB. *Intervent Oncol 360.* 2016;4(6):E101-111. https://clinicaltrials.gov/ct2/show/NCT02685631

Refining Strategy to Drive Growth

A focus on SIR-Spheres Y-90 resin microspheres

Short Term – Stabilisation & costs

Appointment of experienced management into key roles

- Mr Nigel Lange, Group Interim CEO
- Mr Tony Dixon, CEO – EMEA
- Mr Reuben Teo, CEO – APAC

Targeted cost reduction measures

- Targeted cost savings of $7 million (annualised) across non SIR-Spheres microspheres related business functions (principally R&D, admin)
- Minimal restructuring charges

Short Term – Acute focus on our core business

Fully exploit the commercial opportunity of SIR-Spheres microspheres

- Level I evidence, via large randomised controlled clinical studies (first mover advantage)
- Changes to treatment guidelines (NCCN, ESMO, other)
- Submit for expanded indications in the United States in the CY17
- Expanded reimbursement leading to increased patient access (e.g. France)
- Direct sales and marketing infrastructure investment

Wind down of non-core R&D Programs

- Product enhancements and user interface enhancements associated with SIR-Spheres microspheres will continue
- Carbon-Cage Nanoparticles (CCN), Polymer-Coated Nanoparticles (PCN) and radioprotector will be wound down and development ceased beyond contractual obligations – divesture if possible
- Will undertake Histone Inhibition Program (HIP) lead compound STC314 Phase 1 in 2H17, then evaluate commercial options on results

SIRTeX

Medium to long term: Expansion

Expansion Strategy for SIR-Spheres microspheres

- New markets – Latin America, Japan, China
- New applications of SIR-Spheres microspheres
  - Kidney Cancer (RESIRT)
  - Lung Cancer
  - Other
- Product enhancements
- User enhancements

Capital Management – Share buy-back

- Sirtex to undertake an on-market share buy-back program
- Buy-back for up to $30.0 million (2 million shares) over a six month period commencing from 9 March 2017
- No shareholder approval required (within “10/12” Limit)
- Improves capital efficiency, prudent use of strong cash position while providing flexibility to pursue growth and investment opportunities moving forward
- Company reserves the right to suspend or terminate the buy-back at any time

Outlook – FY17

- No change to FY17 dose sales guidance of 5-11%
- No change to FY17 constant currency EBITDA[1] guidance of $65-74 million
- Acute focus on core SIR-Spheres microspheres business
- Wind down of non-core R&D programs
- Capital management with a $30.0 million on-market share buy-back
- Clinician Lunch and Learn and Sirtex clinical strategy presentation/webcast on 2 March in Sydney. Seats available; email acrannage@sirtex.com
- Results of SARAH, SIR*ve*NIB, SIRFLOX/FOXFIRE/FOXFIRE Global studies

[1] Constant currency was applied by restating the full year FY17 with the full year FY16 average rates: Full Year: AUD/USD – 0.724, AUD/EUR – 0.656, AUD/SGD – 1.012. A determination of the constant currency effect for EBITDA has not been subject to external review or audit or prepared in accordance with Australian Accounting Standards, IFRS or the Corporations Act 2001. Constant currency provides one measure of comparability between the periods.

Thank you

SIRTeX